Synaptogenix (NASDAQ:TAOX) Releases Earnings Results

by · The Markets Daily

Synaptogenix (NASDAQ:TAOX – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($1.83) earnings per share (EPS) for the quarter, Zacks reports.

Synaptogenix Price Performance

Shares of NASDAQ TAOX opened at $3.48 on Friday. Synaptogenix has a 1-year low of $3.18 and a 1-year high of $10.00. The business’s fifty day moving average price is $3.62 and its two-hundred day moving average price is $4.41. The firm has a market capitalization of $26.00 million, a PE ratio of -0.26 and a beta of 1.45.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TAOX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a research report on Friday, July 17th. Wall Street Zen raised shares of Synaptogenix from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Get Our Latest Stock Report on Synaptogenix

Synaptogenix Company Profile

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.

Featured Stories